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Abstract 
Introduction: Ghrelin and glucagon-like peptide-1 (GLP-1) are peripherally secreted 
hormones from the gut.  GLP-1 is secreted from the distal gastrointestinal tract in 
response to a meal and is involved in the insulin response and energy homeostasis. 
Ghrelin is secreted mainly from the fundus of the stomach and has been shown to 
increase appetite.  Although both hormones have been linked to the development of 
obesity and diabetes, data is lacking as to how GLP-1 and ghrelin respond to a positive 
energy challenge (PEC) and whether the response differs according to obesity status. 
Thus the present study was designed to investigate the response of these functionally-
related gut hormones to a period of energy surplus (overfeeding). 
Methods:  A total range of 68-72 young men (68 in the ghrelin study, 72 for GLP-1) 
were overfed 70% more calories than baseline requirements for 7 days. Fasting blood 
samples, anthropometric measures and body composition utilizing dual-energy X-ray 
absorptiometry (DXA) were taken pre- and post- overfeeding.  Biochemical markers 
measured included glucose, insulin, cholesterol, HDL-C, LDL-C, and triglycerols. Serum 
total GLP-1 and acylated ghrelin were measured using enzyme-linked immunosorbent 
assays (ELISA) and enzyme immune assays (EIA), respectively.  
Results: As expected, serum GLP-1 increased in response to the energy surplus, however 
unexpectingly, circulating acylated ghrelin also increased. The increase in both GLP-1 
and ghrelin were independent of adiposity status. At baseline, there was no difference in 
fasting GLP-1 and ghrelin between the normal weight, overweight, and obese groups. In 
the overweight/obese cohort, baseline GLP-1 concentration was negatively associated 
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with HDL-cholesterol and positively associated with triacylglycerols and markers of 
insulin resistance. Also in the overweight/obese subjects, a negative relationship was 
present between baseline GLP-1 concentration and change in percent gynoid fat. Baseline 
acylated ghrelin was inversely correlated with weight and BMI in the normal weight 
group and inversely correlated with BMI in the overweight group. Additionally, baseline 
acylated ghrelin was negatively associated with change in weight and BMI in the 
overweight group and positively associated with the same variables in the obese group. 
Percentage change in GLP-1 was positively associated with percentage change in 
triacylglycerols in both the normal weight and overweight/obese groups. Percent change 
in GLP-1 was negatively correlated with percent change in gynoid fat in the normal 
weight group and positively correlated with percent change in cholesterol in the 
overweight/obese group. 
 
Conclusion:  Serum GLP-1 and ghrelin increased in response to a 7-day overfeeding 
period in young Newfoundland men, regardless of obesity status. Our results suggest a 
protective role for GLP-1, increasing to counteract the energy surplus. We also suggest 
that the increase in ghrelin is attempting to offset the rise in insulin resistance.  
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CHAPTER 1: INTRODUCTION 
INTRODUCTION TO OBESITY 
Prevalence and health consequences  
The World Health Organization (WHO) estimates that more than 200 million men 
and 300 million women are obese, globally [1]. Additionally, the organization has 
predicted that by 2015, approximately 2.3 billion and 700 million adults will be classified 
as overweight and obese, respectively [1]. Not only is the current obesity epidemic 
present in adult populations, but childhood rates of obesity have drastically increased [2]. 
Once thought to be a problem of only developed nations, obesity has now become 
prevalent in developing nations [3]. This is evident as about 65% of the global population 
reside in countries in which carrying excess body fat results in greater mortality than 
being underweight [1]. Obesity, or the excessive accumulation of adipose (fat) tissue, is a 
major health concern as it is associated with a number of health complications including 
type-II diabetes, hypertension, cardiovascular diseases, and certain forms of cancer [4]. 
This is of great interest to Newfoundland and Labrador as the province has one of the 
highest rates of obesity in Canada [5]. Moreover, diabetes places immense stress on the 
health care system. The Canadian Diabetes Association has projected that by 2020, more 
than 15% of Newfoundlanders and Labradoreans will be classified as diabetic with an 
estimated health care cost exceeding $360 million dollars, annually [6]. 
Currently, there are many methods to define obesity status; in other words, 
classifying an individual as underweight, normal weight, overweight or obese. The most 
widely used method to determine obesity status has been utilizing body mass index 
(BMI): dividing a person’s weight in kilograms by the square of his/her height in metres 
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(kg/m2). According to the WHO, a BMI of 25 kg/m2 or greater is classified as overweight, 
while a BMI of 30 kg/m2 or greater is classified as obese. BMI has been criticized for 
inaccurately representing body composition but many large population based studies use 
the method for its simplicity [7]. Additionally waist circumference measurements and the 
ratio of waist to hip circumferences have been utilized to estimate central adiposity. Skin 
fold measures using caliper [8], bioelectrical impedance analysis (BIA) [9] and air 
displacement plethysmography (ADP) [10] have also been used to estimate body fat. The 
gold standard for quantifying body fat was originally hydrodensitometry (underwater 
weighing) [11] but now greater precision and simplicity is found using dual-energy X-ray 
absorptiometry (DXA) [12]. DXA works on the principle that adipose tissue is less dense 
than muscle (and bone) and can differentiate between the three tissues based on the 
different densities. Still more accurate measures are evident when using MRIs [13] and 
CT scans [14], but due to the expensive operative costs, these are not usually employed in 
large-scale studies. 
Aetiology 
Recently, the American Association of Clinical Endocrinologists (AACE) has 
declared obesity as a disease [15]. In general, obesity results from a chronic positive 
caloric balance: energy intake (caloric intake) is greater than energy expenditure (basal 
metabolic rate, thermic effect of food/adaptive thermogenesis, and physical activity) [16]. 
The easy accessibility/overconsumption of calorically dense foods and the lower physical 
activity requirements contribute to the chronic energy imbalance. However, obesity is a 
multifaceted condition and thus, factors including genetic predisposition and the 
environment do influence one’s susceptibility to gain weight (or lose weight). Various 
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environmental cues including the weather, culture, industry marketing, portion size, price 
of food and potential food addictions have been thought to have a role in the increasing 
prevalence of obesity [17]. Currently, walkability scores of communities have been 
calculated, and used to assess relationships with obesity [18, 19]. However, strong 
evidence that environmental factors have an influence on body weight and adiposity are 
found in populations which have a common genetic background but due to a changing 
environment, weight gain has ensued. For example, Pima Indians who reside in the 
United States carry 25 kg more body weight as compared to Pima Indians residing in 
Mexico [20].   
Moreover, genetics factors are theorized to play a pertinent role in obesity as 
variants in many candidate genes have been associated with human obesity, and rare 
monogenic forms of obesity have also been observed [21, 22]. Twin studies have 
estimated the heritability (how much is genetics playing a role in differences of a given 
trait) of obesity ranges from 64-84% (based on BMI) [23-25]. Interestingly, studies have 
found strong relationships between individuals who were adopted and their biological 
parents [23]. Various linkage studies have found evidence for quantitative trait loci (QTL) 
affecting obesity-related traits [26, 27]. Additionally, several polymorphisms have been 
found in association studies to be linked with obesity-phenotypes [28, 29]. For example, 
FTO (fat mass and obesity-associated gene) was found to be associated with obesity in 
both a genome-wide association study (GWAS) and a genetic association study [30, 31]. 
Interestingly, a polymorphism in the MC4R receptor gene (V103I) has been associated 
with protection against weight gain and obesity [32]. Many monogenic obesity syndromes 
exist with mental retardation and/or the developmental anomalies including Prader-Willi 
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Syndrome [33, 34], Bardet-Biedl Syndrome [35, 36], and TRKB deficiency [37]. As well, 
monogenic forms of obesity have been observed without the presence of the stated 
developmental issues. Congenital leptin deficiency (ob/ob mice) [38], leptin receptor 
deficiency (db/db mice) [39, 40], POMC deficiency [41] and melanocortin 4 receptor 
deficiency are all examples of rare monogenic forms of obesity [42, 43]. 
It must be noted however, that physiological mediators of the endocrine system 
(hormones) influence energy equilibria and thus, obesity status [44]. Various hormones 
play an important role in energy homeostasis, appetite regulation, adipose distribution and 
therefore, human obesity and related health complications. Hormones secreted into the 
circulation from peripheral tissues interact with complex metabolic pathways including 
regulation in the central (CNS) [45]. For example, the adipokine leptin, is secreted in 
proportion to fat mass and inhibits food intake [46]. The ob/ob mouse model, first 
discovered in the 1950s, lacks the ability to code for the functional leptin protein, and 
thus ob/ob mice become severely obese [38, 47]. Furthermore, hormones secreted from 
endocrine cells of the gastrointestinal (GI) tract also play a role in energy homeostasis 
[48, 49]. Peripheral secreted signals from the GI tract are referred to as gut hormones, and 
have a wide range of functions including: decreasing (or increasing) appetite, modulation 
of glucose and lipid metabolism or insulin sensitivity, and GI motility. The hormones are 
secreted into circulation from specific locations through the GI tract (i.e. stomach, 
duodenum) and bind to receptors in various tissues and as mentioned, the CNS [48, 49]. 
Ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), pancreatic polypeptide 
(PP), cholecystokinin (CCK), and amylin are all examples of hormones released into the 
blood from the gut. In all there are over 20 gut hormones present in humans. However, 
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the remainder of this thesis manuscript will focus on the gut hormones ghrelin and GLP-
1. 
 
INTRODUCTION TO GHRELIN 
Ghrelin is 28-amino acid peptide secreted mainly from the endocrine cells (X/A-
like cells) of the fundus (stomach) but is also found in the central nervous system (CNS) 
[50-52]. It was discovered in 1999, and is the only endogenous ligand of the growth 
hormone secretagogue receptor (GHS-R) [53]. The ghrelin gene (GHRL) is found on 
human chromosome six which encodes a preproghrelin molecule, that when cleaved, 
forms ghrelin [54]. The active ghrelin molecule contains a posttranslational acylation 
modification: its 3rd amino acid (serine) is n-octanoylated [52, 55]. Ghrelin rises in 
response to lack of nutrients in the gut; its circulating concentration rises during fasting, 
and peaks just before consumption of a meal [56, 57]. The concentration then decreases in 
proportion to the food intake and drops to a minimum value roughly one hour post meal.  
Because of this, ghrelin is thought to be a hunger signal, increasing appetite and thus 
inducing food intake [58, 59]. Circulating active ghrelin binds to its receptor in various 
tissues including the central nervous system and has a half-life of about 30 minutes [60]. 
Ghrelin can act directly in the CNS, specifically at the arcuate nucleus of the 
hypothalamus, to increase appetite [61]. Injections of ghrelin (ICV) increase the level of 
the orexigenic hormone neuropeptide Y’s (NPY) mRNA in the arcuate nucleus [62, 63].  
It is interesting to note that most cross-sectional studies have found a negative association 
between adiposity and ghrelin: lean individuals have higher levels of circulating ghrelin 
as compared to their obese counterparts [64-69]. However other studies have found 
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dissimilar findings: both positive and lack of association between ghrelin and increased 
adiposity [70, 71]. Moreover, high ghrelin concentrations are found in the inherited 
disease of Prader-Willi [72-74], which is characterized by uncontrollable appetite, and 
also in cases of anorexia nervosa, where there is little appetite [75, 76]. Administration of 
ghrelin in animal models and humans increases appetite and food intake [77-80]. 
Interestingly, it has been shown that, when ghrelin receptor knockout mice (GHSR-null) 
are fed high fat diets, they consume less food and have less body fat as compared to 
controls [81]. When ghrelin receptor knock-out mice are administered ghrelin, the 
signature enhancement of appetite is absent (as well as the increase in growth hormone) 
[82].  Additionally nutritional factors could influence ghrelin concentration as high-fat 
meals decrease circulating levels of the hormone [83, 84]. Therefore ghrelin is thought to 
be involved in energy homeostasis regulation and related conditions (i.e. human obesity) 
and has even been ascribed in the newly investigated concept of ‘food addiction’ [85]. 
 
INTRODUCTION TO GLP-1 
Glucagon-like peptide-1 (GLP-1) is a 30 amino acid peptide secreted into 
circulation by the L-cells of the distal  GI tract in response to nutrients in the gut [86]. 
GLP-1 is encoded from same gene as glucagon (GCG) which is located on human 
chromosome two. Due to tissue-specific posttranslational modification, the gene product 
proglucagon, is cleaved by prohormone convertase forming active GLP-1 [87]. The half-
life of GLP-1 is extremely short; it is degraded in circulation within ~2 minutes by 
dipeptidyl peptidase-IV (DPP-IV) [87, 88]. There is one known receptor for GLP-1 
(GLP1R) which has been found both centrally and peripherally [89-91]. Once bound to its 
7 
 
 
receptor, GLP-1 elicits a number of responses which in general, helps to establish a more 
favourable insulin response. GLP-1 is considered an incretin hormone, as it facilitates the 
glucose-dependent insulin secretion [92, 93]. In fact, it has been suggested that GLP-1 
and related incretin hormones are responsible for about 2/3 of the insulin response once 
food is ingested [94]. Additionally, GLP-1 has been shown to decrease the secretion of 
glucagon from the alpha cells of the pancreas [95-97]. A study on type-I diabetics, who 
have little or no β-cell activity, observed that GLP-1 could lower fasting blood glucose, 
independent of influencing insulin secretion [95]. GLP-1 also acts to inhibit gastric 
motility and GI secretions [98, 99]. Satiation has also been shown to be influenced by 
GLP-1 as the hormone has been observed to decrease appetite [100-102]. It is of interest 
to note GLP-1 receptor knockout (GLP1R -/-) mice are deemed glucose intolerant though 
they do not become obese [103]. Holst et al. credits this phenomena to the redundancies 
present in appetite regulation pathways [86]. In regards to adiposity status, GLP-1 
secretion is greater in lean individuals as compared to their obese counterparts [104]. Also 
type-II diabetics who are insulin resistant, have a blunted GLP-1 response [105] and 
therefore, treatment with GLP-1 or GLP-1 receptor agonists have resulted in an improved 
insulin response [106, 107]. In addition, DPP-IV inhibitors have been utilized in the 
condition as they act to increase the half-life of GLP-1 [108]. Recently, both GLP-1 
agonists and DPP-IV inhibitors have been studied in regards to human obesity [109, 110]. 
 
OVERFEEDING AS A METHOD TO STUDY OBESITY: ENDOCRINE 
INVOVLEMENT 
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Aforementioned, obesity is caused by a chronic energy surplus (positive energy 
balance) in which energy intake exceeds energy expenditure [4]. Individuals overfed 
more calories than they expend, will store this excess fuel in the form of triglycerides in 
adipose tissue, consequently causing increased fat mass. In the study of obesity, the 
positive energy challenge is of great interest to researchers as metabolic and physiological 
changes induced during a period of overfeeding aid in further understanding human 
obesity. Many animal models have been used in overfeeding intervention studies. 
Specifically in rat and mice models, high fat diets have been utilized to induce 
overfeeding as fat is the most calorically dense macronutrient [111]. Studies in the past 
have provided rats/mice with diets containing 30-78% of calories from fat [112], through 
feeding of a cafeteria style diet or by simply adding a portion of lard to food [113-116]. 
Moreover, researchers have implemented overfeeding studies on humans, as due to 
underlying physiological differences, animal model intervention-based research does not 
always translate into similar results in humans. In fact, a number of overfeeding studies in 
human have been completed, however they differ in various aspects including: length of 
overfeeding period, macronutrient composition of overfeeding, degree of overfeeding, 
participant demographics and number of participants. One of the earlier human 
overfeeding studies was completed between 1964 and 1970 by Ethan Sims, a researcher 
at the University of Vermont [117]. This study named “The Vermont Prison 
Experiments”, took place through a 10-week period in which inmates were overfed nearly 
three times the amount of calories they would normally intake [117-119]. On average, the 
subjects’ caloric intakes ranged from about 8,000-10,000 kilocalories per day. After the 
10-weeks of overfeeding, the men gained 15-25% of their originally weight (average 
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weight gain of 36 pounds) and most of the gain due to an increase in total body fat. The 
study was used for many investigations including: 1) observing adipose tissue changes 
through the duration of overfeeding (adipose tissue biopsies) and 2) observing changes in 
various hormones (i.e. thyroid hormone) through the duration of obesity [119-121]. 
Another human overfeeding study was completed by Claude Bouchard’s research group 
and published in the New England Journal of Medicine in 1990 [122]. In this study 
twelve pairs of male twins (monozygotic) were fed an energy surplus of 1000 kcal per 
day, for six days out of a seven-day week. The duration of the study was 100-days so 
each subject was overfed for 84 days totalling an excess of 84,000 kcalories. The weight 
gain ranged from 4.3 – 13.3 kilograms with a mean weight gain of 8.1 kg [122]. The 
group theorized that similarity in weight gain found between twins was due to genetic 
influences. Therefore as indicated through the previously mentioned studies, human 
overfeeding studies have been utilized to study obesity in the past.  
From overfeeding studies in both our lab and others, it has been observed that an 
energy surplus can change anthropometrics, body composition, genetic expression and 
circulating hormones [123-127]. However human positive energy challenge studies 
investigating the response of various gastrointestinal hormones, specifically peptides 
(ghrelin, GLP-1, etc) released from the gut involved in energy homeostasis are few in 
number [128]. Therefore the current research goal of this thesis was to investigate the 
potential role of circulating ghrelin and GLP-1 on the development of human obesity by 
examining: 1) the response of fasting circulating acylated ghrelin  and GLP-1 
concentrations in normal weight, overweight, and obese males to short-term overfeeding; 
2) fasting circulating acylated ghrelin and GLP-1 concentrations in each adiposity group 
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before/after overfeeding; and 3) the relationships of fasting circulating acylated ghrelin 
and GLP-1 concentrations with anthropometrics, body composition, fasting glucose, 
insulin, and blood lipids concentrations, and insulin resistance state, before and after 
overfeeding.
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ABSTRACT 
Background: Ghrelin, an orexigenic gut hormone secreted primarily from the stomach, is 
involved in energy homeostasis. However, little data is available regarding its response to energy 
surplus and the development of human obesity. 
Objective: The present study investigated the response of circulating acylated ghrelin to a 7-day 
positive energy challenge. 
Design: A total of 68 healthy young men were overfed 70% more calories than required, for 1-
week. Subjects were classified based on percent body fat (measured by dual-energy X-ray 
absorptiometry) as normal weight, overweight, and obese. Serum acylated ghrelin concentration 
was measured before and after the positive energy challenge. Additionally, the relationship 
between acylated ghrelin and obesity-related phenotypes including weight, body mass index, 
percent body fat, cholesterol, HDL-c, LDL-c, glucose, insulin and homeostasis model assessment 
of insulin resistance and β-cell function at baseline and change due to overfeeding, were 
assessed. 
Results: Contrary to our expectations, serum acylated ghrelin was significantly increased in 
response to overfeeding and the increase was independent of obesity status. There was no 
significant difference in fasting acylated ghrelin between normal weight, overweight, and obese 
men at baseline. Acylated ghrelin was negatively correlated with weight and BMI for normal 
weight and with BMI in overweight men. Also ghrelin was correlated with change in weight and 
BMI in overweight (negative relationship) and obese (positive relationship) groups. 
Conclusion: Our results showed that circulating acylated ghrelin was increased after a 7-day 
positive energy challenge regardless of adiposity status. However, acylated ghrelin was 
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correlated with change in weight and BMI in opposing directions, in overweight and obese 
subjects respectively, thus dependent on obesity status. 
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INTRODUCTION 
Although  it has been well-established that appetite is controlled through complex 
mechanisms mainly in the central nervous system (CNS), appetite-regulating hormones secreted 
from the periphery, including the gastrointestinal tract (gut), communicate with the CNS to play 
an important role in energy homeostasis [1-3]. Ghrelin, an endogenous ligand of the growth 
hormone secretagogue receptor (GHS-R), is the only known orexigenic gut hormone, which 
increases appetite and food intake [4-6]. Ghrelin is found in both the gastrointestinal tract and 
hypothalamus, though it is primarily synthesized and released from X/A like cells of the gastric 
mucosa of the stomach [4, 7-9]. Both acylated and non-acylated forms of ghrelin exist, however 
the active form is n-octanoylated on the third amino acid (serine) residue [4, 10, 11]. Ghrelin is 
thought to be a meal initiator: concentration rises prior to feeding, and continually decreases to a 
minimum one-hour after the meal [12, 13]. The postprandial suppression of circulating ghrelin is 
proportional to the caloric content of the consumed meal [14].  
Many studies have investigated ghrelin’s role in the regulation of appetite and energy 
homeostasis. Administration of ghrelin in both rats and humans has been shown to increase 
appetite and food intake [6, 15-18]. However in humans, most studies have found a negative 
relationship between ghrelin and adiposity: higher circulating ghrelin concentrations in lean 
individuals as compared to obese [19-24]. In contrast, other studies have found positive 
relationships between acylated ghrelin concentrations and markers of adiposity [25] or a negative 
relationship with BMI and no relationship to body fat [26]. Additionally, a growing body of 
evidence shows that ghrelin might have a role in insulin resistance and development of type-II 
diabetes. Animal studies have shown that ghrelin can inhibit insulin secretion, but increases 
glucagon secretion from pancreatic islet cells [27]. Moreover human studies reveal that patients 
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with insulin resistance have lower ghrelin concentrations compared with insulin-sensitive 
patients [28]. 
Circulating ghrelin concentration seems to be influenced through dietary regulation and 
specific nutrient intakes. For example, a high-fat meal has been shown to decrease circulating 
ghrelin concentration in humans [29, 30]. Moreover, our laboratory and others have revealed 
changes in nutritional status, such as overfeeding influence adipokine and gut hormone 
concentrations [31, 32], adipose tissue metabolism [33, 34] and genomic expression [35]. 
Intervention based studies, observing nutritional regulation via a positive energy challenge, are 
also important in understanding the role of ghrelin in the development of human obesity where 
energy surplus is the major driving factor [36-40]. Currently, data is missing in this aspect.  
Our current research goal was to investigate the potential role of acylated ghrelin on the 
development of human obesity by examining: 1) the response of fasting serum acylated ghrelin 
concentrations in normal weight, overweight, and obese males to short-term overfeeding; 2) 
fasting serum acylated ghrelin concentrations in each adiposity group before and after 
overfeeding; and 3) the relationships of fasting serum acylated ghrelin concentrations with 
fasting glucose and insulin concentrations, blood lipids, and insulin resistance state, before and 
after overfeeding. 
 
MATERIALS AND METHODS 
Ethics Statement 
All participants provided informed and written consent. The current study received 
ethical approval from the Human Investigations Committee for the Faculty of Medicine, 
Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada. 
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Subjects  
A total of 68 young males from the Canadian province of Newfoundland and Labrador 
were recruited to study the effects of an acute positive energy balance on metabolism and various 
endocrine factors (original study contained 72, underweight participants were eliminated from 
analyses). Participation criteria included: 1) age 19-29 years; 2) at least of 3rd-generation 
Newfoundland descent; 3) no serious cardiovascular, metabolic, or endocrine diseases; 4) no 
medications intended for lipid metabolism change; and 5) a stable 6-month reported body weight 
value (±2.5 kg). Recruited subjects were asked to refrain from 1) consuming alcoholic or 
additional calorie-containing beverages and from 2) taking any drugs or medication, throughout 
the duration of the research study.  
 
Serum Measurements 
Blood samples were collected from all subjects both before and after completion of the 
positive energy challenge (explained below). Serum was prepared from clotted samples collected 
after a 12 hour fast which were stored at -80 o C until time of further analysis. Serum acylated 
ghrelin concentrations were measured in duplicate with enzymeimmunosorbent assay (EIA) kits 
(Bertin Pharma; Montigny le Bretonneux, France). Acylated ghrelin analyses were performed on 
ice.  The concentrations of serum total cholesterol, high-density lipoprotein (HDL) cholesterol, 
triacylglycerols (TG), and glucose were analyzed using Synchron reagents by an Lx20 clinical 
chemistry analyzer (Beckman Coulter Inc., CA, USA). Low-density lipoprotein (LDL) 
cholesterol was calculated by the Friedwald equation: total cholesterol – HDL – TG/2.2 (which 
is a reliable estimate in the absence of severe hypertriglyceridemia >4.6 mmol/L). Serum insulin 
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was evaluated using an Immulite 2500 immunoassay analyzer (Siemens, Los Angeles, CA). 
Insulin resistance and pancreatic β-cell function were assessed using the homeostasis model 
assessment (HOMA). Insulin resistance was quantified using HOMA-IR [insulin (mU/L) x 
glucose (mmol/L)/22.5)] while β-cell function was measured using HOMA-β [20 x insulin 
(mU/L/(glucose (mmol/L) - 3.5)].  
 
Body composition assessment 
Dual-energy X-ray absorptiometry (DXA Lunar Prodigy; GE Medical Systems, Madison, 
WI) was used to measure body composition (lean tissue, body fat, and bone mineral 
composition). Following a method previously described by us [41] the participant was scanned in 
a supine position after a 12-hour fast and the following parameters were determined from the 
DXA scan: total percent body fat (%BF), percent trunk fat (%TF), percent android fat (%AF), 
and percent gynoid fat (%GF). All measurements were performed before overfeeding and on the 
day after overfeeding. 
 
Anthropometric measurements 
Measurements of body weight, height, waist circumference, and hip circumference were 
performed after a 12-hour fasting period. Body weight was measured to the nearest 0.1 kilogram 
on a platform manual scale balance (Health O Meter, Bridgeview, IL) with subjects wearing a 
standardized hospital gown. A fixed stadiometer was used to measure height to the nearest 0.1 
centimeters (shoes removed). A flexible measuring tape was employed to measure waist 
circumference to the nearest 0.1 centimeters at the level of the umbilicus. The same procedure 
was used to measure hip circumference at the level of largest circumference between the waist 
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and thighs. Body mass index (BMI) was calculated by dividing participants’ weight in kilograms 
by the square of height in centimeters [(weight-kg)/(height-m)2].  
 
Overfeeding protocol 
Participants enrolled into a 7-day positive energy challenge and were required to 
consume 70% more calories than their normal food intake. Throughout the challenge period, 
subjects followed a diet consisting of 15% protein, 35% fat, and 50% carbohydrates, thus 
mimicking typical North American dietary patterns. A 7-day positive energy challenge was 
selected to ensure that metabolic changes were induced throughout its duration. Individual 
energy requirements were recorded and estimated before commencing the overfeeding protocol 
by the use of three 24-hour recalls and a 30-day dietary inventory. For one week at time 0900, 
1200, and 1700, participants were offered meals of which caloric and macronutrient content was 
assessed using FOOD PROCESSOR SQL software (version 9.5.0.0; ESHA Research, Salem, 
OR). The average baseline energy intake before and during overfeeding were 2969 kcal and 
5471 kcal, respectively. A detailed overfeeding protocol has been described in our previously 
published papers [33, 34]. 
 
Statistical analysis 
Data are presented as means ± SE unless otherwise stated. Prior to analysis, data that 
showed a skewed distribution was logarithmically transformed to approximate a normal 
distribution. Concentration data for serum acylated ghrelin, triacylglycerols, insulin, and HOMA-
IR and HOMA-β, all at baseline, after, and change during overfeeding were log transformed 
prior to analysis. Using criteria suggested by Bray [42] subjects were classified as either normal 
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weight, overweight or obese based upon %BF (8-20.9, 21-25.9 and ≥26%, respectively). 
Subjects were also classified using the World Health Organization BMI-based classification 
(BMIs of ≤24.9, 25.0-29.9, and ≥30 kg/m2 for normal weight, overweight, and obese 
respectively). Because of its more accurate classification of obesity status, Bray Criteria was 
used for subsequent analyses.  
Using a two-factor analysis of variance (ANOVA) with repeated measures before and 
after overfeeding, differences in physical and biochemical variables in response to overfeeding 
were assessed between the three groups. One-factor analysis of variance was used to compare 
baseline values between the three adiposity groups. Variables which showed a significant 
overfeeding-adiposity interaction underwent within-group analysis of the response to 
overfeeding using a paired t-test. In both one factor and two-factor ANOVA analyses, 
Bonferroni post hoc tests were employed. 
Initial Pearson’s correlation analyses were performed to assess relationships between 
fasting acylated ghrelin concentration and physical/biochemical variables of interest. Next we 
performed two correlation analyses: 1) baseline acylated ghrelin concentration was compared 
with all variables at baseline and 2) baseline acylated ghrelin concentration was compared with 
changes in all variables in response to overfeeding thus examining if baseline acylated ghrelin 
could predict the changes in related physical and biochemical markers. All statistical analyses 
were completed using SPSS, version 19.0 (SPSS Inc, Chicago) in which: 1) all tests were two-
sided; and 2) a P value < 0.05 was deemed statistically significant. 
 
RESULTS 
Descriptive Statistics 
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Basal physical and biochemical characteristics of subjects are shown in Table 1. 
Differences in body composition and glucose, and lipid metabolism between normal-weight, 
overweight, and obese (based on %BF) young healthy men were previously described by us [31, 
33-35]. 
Baseline fasting acylated ghrelin concentrations (mean ± S.E.) for normal weight, 
overweight, and obese individuals were 222.19 ± 41.60, 274.91 ± 92.4, and 352.03 ± 112.4 ng/L, 
respectively. There was no statistically significant difference between adiposity groups for 
acylated ghrelin concentration at baseline. Similar results were obtained when participants were 
divided into normal weight, overweight and obese groups based on the World Health 
Organization’s BMI classification (data not shown). 
Changes in body composition and phenotypes of glycemic control and lipid metabolism 
in response to the 7-day overfeeding challenge are also described in Table 1. Within all adiposity 
groups, the positive energy challenge increased body composition, serum lipids, insulin 
resistance, and pancreatic beta cell function, which was previously described by us [31, 33-35]. 
In response to the 7-day overfeeding challenge, circulating acylated ghrelin concentration 
significantly increased by 62.14 ng/L in the entire cohort (P=0.042). However, no adiposity-
overfeeding interaction was present; the response of acylated ghrelin to overfeeding was not 
significantly different between normal weight, overweight, and obese groups (P=0.523). 
 
Correlations of acylated ghrelin with adiposity and phenotypes of glucose and lipid 
metabolism 
Partial correlation analyses, controlling for age, were used to assess the relationships 
between baseline fasting acylated ghrelin concentration and baseline phenotypes of adiposity, 
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and serum glucose and lipid concentrations (Table 2). For normal weight subjects, acylated 
ghrelin was negatively correlated with weight and BMI (P < 0.05). Furthermore, fasting glucose 
concentration was positively correlated with acylated ghrelin concentrations. The significant 
negative correlation between acylated ghrelin and BMI was also observed in overweight 
subjects, but not in obese subjects. LDL cholesterol was negatively correlated with acylated 
ghrelin concentration only in obese subjects. 
Additionally, partial correlation analyses examining the relationship between baseline 
acylated ghrelin concentration and changes in variables after the overfeeding period were used to 
examine if acylated ghrelin concentration could predict variable change under a positive energy 
challenge (Table 3). Significant negative relationships were found for the overweight group, 
between baseline acylated ghrelin concentration and change in body weight and BMI. However, 
the relationship between baseline acylated ghrelin and change in body weight and BMI, were 
positive for obese subjects. 
 
Acylated ghrelin Tertiles: Correlations of acylated ghrelin with phenotypes of adiposity 
and concentrations of glucose and lipids 
We repeated all of the above analyses after participants were divided into acylated 
ghrelin tertile subgroups (low, medium, and high ghrelin; data not shown). Only one baseline 
correlation existed within the analysis. For the high ghrelin subgroup, baseline acylated ghrelin 
was positively correlated with baseline fasting triacylglycerols. No significant relationships were 
found when partial correlation analyses were performed examining baseline acylated ghrelin 
concentrations and changes in the aforementioned variables. 
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DISCUSSION 
The most important finding from the present study was the discovery of the significant 
increase in serum acylated ghrelin concentration after the 7-day positive energy challenge. 
Conventional knowledge would lead us to expect that to counteract a positive energy balance 
(thus limiting caloric intake) during overfeeding, secretion of ghrelin would be diminished to 
decrease appetite. However, the results from our study was surprisingly the opposite; acylated 
ghrelin concentration significantly increased after the 7-day overfeeding challenge regardless of 
adiposity status. Pathologically high circulating concentrations of ghrelin are known to occur in 
the inherited disease of Prader-Willi Syndrome, which is characterized by uncontrollable appetite 
[43-45], but also in cases of anorexia nervosa, where there is little appetite [46, 47].  
At the present time, results are not clear based on limited studies examining the 
responsiveness of ghrelin to a positive energy challenge. Moreover, the few available studies 
with positive energy challenge interventions differ in many aspects including length of 
overfeeding, macronutrient composition, amount of food consumed above daily caloric 
requirements, and also the physical and demographic characteristics of the study participants. 
Hagobian et al. overfed 9 healthy subjects (6 men and 3 women) 25% more calories than 
required for weight maintenance for 3 days, retaining a macronutrient composition of 56% 
carbohydrate, 29% fat, and 15% protein, and found no significant change in circulating ghrelin 
concentration [38]. Votruba et al. overfed 69 non-diabetic, mainly obese individuals (40 men and 
29 women) 60% more calories than required at baseline from a “vending machine diet” over a 3-
day period [37]. Circulating ghrelin concentration did not change through the 3-day duration. A 
5-day high fat (60% fat, 32.5% carbohydrates and 7.5% protein) overfeeding study (50% more 
calories than required) found a non-significant increase in circulating ghrelin in a cohort of 26 
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healthy young men [36]. Robertson et al. overfed 6 healthy lean male subjects by ~692.7 
kcal/day with a high fat diet ranging from 29-45% calories from fat. This study detected no 
significant change in fasting ghrelin, however, postprandial ghrelin was suppressed to a greater 
extent following the oral fat tolerance test [39]. Finally, a long-term overfeeding study of 100-
day in which twelve pairs of identical twins consumed an excess of 84,000 kilocalories (50% 
carbohydrates, 35% fat, and 15% protein) revealed a non-significant decrease in plasma ghrelin 
concentration [40]. Our current study using a typical North American diet (15% protein, 35% fat, 
and 50% carbohydrates) and a homogenous large sample size consisting of only young male 
university students, detected a significant increase in circulating acylated ghrelin after 7 days of 
overfeeding. The reason for the increased acylated ghrelin concentration after the positive energy 
challenge is not clear. In animal studies, the infusion of ghrelin has been shown to result in 
inhibition of beta-cell function and insulin secretion, but also an increase in insulin sensitivity 
[27, 48, 49]. Additionally in cross-sectional human studies, fasting ghrelin is negatively 
associated with insulin resistance [50]. It is therefore possible that the increased ghrelin secretion 
due to overfeeding was a counteractive response to the rising insulin resistance after the 7-day 
overfeeding, though this is purely speculative as multiple factors must be in play. However, the 
role of this increased response by ghrelin in long-term energy homeostasis, including the 
development of human obesity, warrants further study. 
Although it has been reported that circulating ghrelin is higher in lean individuals than 
overweight and obese individuals [19-24], our cohort showed no significant difference in 
circulating acylated ghrelin among the three adiposity groups. However, when subjects were 
divided according to adiposity status, BMI was negatively correlated with acylated ghrelin 
concentration in both normal weight and overweight subjects. This is in line with the observation 
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that ghrelin may help maintain healthy body weight and BMI. The reason why such correlation 
was not observed in obese subjects is unclear. It is possible that the normal hormonal mechanism 
of ghrelin was dysfunctional in the obese state, as seen for many other hormones [51, 52]. This 
was further demonstrated by the differences in correlations found in overweight and obese 
subjects, between baseline acylated ghrelin and change in weight and BMI. Overweight subjects 
showed a negative relationship, while obese subjects showed a positive relationship, between 
fasting baseline acylated ghrelin and change in body weight and BMI. Thus higher baseline 
acylated ghrelin predicts low weight gain and BMI in the overweight group, but the opposite is 
true of the obese group. This may predispose to further weight gain in obese people. 
Additionally, we sought to examine the association of acylated ghrelin with serum 
indices of lipid and glucose metabolism. The associations between ghrelin and circulating 
lipids/glucose seem to be affected by obesity status. We observed that only baseline acylated 
ghrelin concentration was positively associated with fasting glucose concentration in normal 
weight subjects. Additionally in obese subjects, acylated ghrelin was negatively related to 
circulating LDL cholesterol concentration. Why these relationships were found in specific 
adiposity groups is unknown. Evidently, more studies are warranted to further grasp the 
physiological association of ghrelin with glucose and lipid metabolism. 
The present study is not without limitations. We only studied young men of the same 
ethnicity thus limiting its potential application to other ethnic, age, or female groups. Future 
large scale studies including females and a wider age range are needed to further understand the 
response of ghrelin to a positive energy challenge. Additionally, it must be noted that ghrelin 
concentrations are affected by meals [53]. However in our investigation, the relationship between 
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ghrelin and aforementioned physiological measurements were completed in a fasting state. Data 
of area under the curve after a standardized meal may provide additional useful information. 
In summary, the response of acylated ghrelin to a short-term positive energy challenge 
was studied in 68 young healthy men. Serum acylated ghrelin was measured before and after a 7-
day overfeeding challenge in 68 young men. Surprisingly, fasting ghrelin concentration was 
significantly increased in response to the positive energy challenge in the entire cohort. Based on 
our finding and the literature, we hypothesize that this increase may counteract the rising insulin 
resistance. At baseline, there were no significant differences in circulating acylated ghrelin 
concentration between normal weight, overweight, and obese men. However negative 
correlations were observed between ghrelin and BMI, in normal weight and overweight subjects. 
The baseline acylated ghrelin concentration correlated with change in weight and BMI in 
opposite directions in overweight and obese subjects. Thus future studies are warranted to 
understand the mechanistic pathway of ghrelin to further elucidate its role in energy homeostasis 
and human obesity. 
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ABSTRACT 
Background: Glucagon-like Peptide-1 (GLP-1) is an incretin hormone secreted from the 
gastrointestinal tract that facilitates the glucose-dependent insulin response. Additionally, GLP-1 
is thought to be involved in energy homeostasis. Currently little is known about GLP-1’s 
responsiveness to an energy surplus, a fundamental cause of obesity and diabetes. Our objective 
was to examine the response of serum GLP-1 to short-term (7 day) overfeeding in young men. 
Methods: Seventy-two young men from the Canadian province of Newfoundland were recruited 
for the study. For 7-days, the subjects consumed 70% more calories than required at baseline. 
Various measurements including: anthropometrics, body composition, markers of glucose/lipid 
metabolism and serum total GLP-1, were taken at a fasted state before (day 1) and after (day 8) 
the challenge. Paired t-test analyses were used to assess the change in variables after the 
overfeeding period. Additionally, the relationship between serum GLP-1 and the measured 
variables at baseline and change due to overfeeding were analyzed. 
Results: Serum GLP-1 was significantly increased in all groups in response to the 7-day energy 
surplus, indicating the increase was independent of adiposity status. There was no significant 
difference in fasting GLP-1 at baseline between the normal weight and overweight/obese groups. 
At baseline, GLP-1 concentration negatively correlated with HDL-cholesterol and positively 
correlated with triacylglycerols and markers of insulin resistance in the overweight/obese group. 
Also GLP-1 was negatively correlated with change in percent gynoid fat in the overweight/obese 
subjects. Percent change in GLP-1 was negatively associated with percent change in gynoid fat 
in the normal weight group and positively associated with percent change in cholesterol in the 
overweight/obese group. Percentage change of circulating triacylglycerols was positively 
associated with percent change in GLP-1 in both adiposity groups. 
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Conclusion: Our findings showed that GLP-1 serum concentration is not a significant factor in 
determining obesity status.  The increase of GLP-1 in all subjects regardless of obesity status, 
suggest GLP-1 serves as a protective role, counteracting energy surplus. 
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INTRODUCTION 
Hormones secreted from the gastrointestinal (GI) tract play an important role as 
peripheral signals of energy homeostasis and are thought to be involved in the development of 
obesity and diabetes [1]. Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone 
secreted from the L-cells of the distal ileum, but is also present in the central nervous system [2]. 
GLP-1 is a product of the GCG gene and is formed due to tissue-specific post-translational 
modification of proglucagon. The hormone is released into circulation in response to food intake; 
the larger the meal size, the greater the GLP-1 response. [3, 4]. Therefore during the fasted state, 
GLP-1 is low (but still detectable) however the concentration rises postprandially. Active GLP-1 
has a very short half-life of ~2 minutes as it is degraded by dipeptidyl peptidase-IV (DPP-IV) [5, 
6].  
GLP-1 binds to its receptors present in a variety of tissues and elicits a number of 
responses. For one, GLP-1 is designated an incretin hormone, facilitating the glucose-dependent 
release of insulin from the pancreatic beta-cells [7, 8]. Also it has been shown to decrease the 
secretion of glucagon in patients with type-I diabetes who have no beta-cell function but still 
exhibit the lowered plasma glucose via GLP-1 [9-11]. Other effects include, decreased appetite 
[12-14] and decreased gastric motility and secretion [15, 16]. 
Due to its many metabolic-related effects, GLP-1 has been implicated in many chronic 
metabolic diseases. For example, both its incretin effect and suppression of glucagon secretion 
action are disrupted in type-II diabetes [17]. It has also been shown that intravenous (IV) 
infusion of GLP-1 acts to lower blood glucose concentration in type-II diabetic patients [18, 19]. 
GLP-1 is also suggested to be involved in obesity as morbidly obese subjects show a decreased 
diurnal L-cell secretion [20]. Fasting GLP-1 has been found to be lower in diabetic and obese 
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diabetic patients as compared to healthy controls [21, 22] however, not all studies have 
consistent findings [23]. Additionally, the postprandial secretion of GLP-1 is inhibited in 
morbidly obese subjects, which is improved after weight loss [24, 25]. It has been found that 
GLP-1 infusions reduce food intake in normal weight and obese subjects, regardless of diabetic 
status [13, 14, 26-28]. 
Recognizing that obesity is a result of a chronic positive energy imbalance, it has been 
shown that modification of food intake, including overfeeding, influence various gut hormone 
concentrations [29-32]. However, most human studies on GLP-1 have been performed using a 
cross sectional study design which may not reflect biological and clinical relevance. The 
dynamic process of  an energy surplus will provide insights of the role of GLP-1 in the 
development of obesity and diabetes [33-35].The objectives of the present study were therefore 
to investigate: a) the GLP-1 response to short-term overfeeding in young men; b) the difference 
in serum GLP-1 concentration in pre- and post- overfeeding between various adiposity groups; 
and c) the relationship of fasting GLP-1 with various obesity-related markers. 
 
METHODS 
Subjects 
Seventy-two healthy men (age 19-29) from Newfoundland and Labrador, Canada, participated in 
the present study. All subjects were of at least 3rd generation Newfoundland descent and reported 
a stable body weight over the last six months. Participants had no serious endocrine, metabolic or 
cardiovascular diseases, nor were taking any medications affecting lipid/cholesterol metabolism. 
Informed and written consent were provided by each subject. Ethical approval was received from 
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the Human Investigations Committee for the Faculty of Medicine, Memorial University, St. 
John’s, NL, Canada. 
 
Overfeeding 
Overfeeding was completed following a protocol previously described by us [31, 32, 36]. To 
assess the metabolic and endocrine effects of a short-term energy surplus, participants were 
overfed, for one week (7 days), 70% more calories than what they would normally consume. A 
7-day overfeeding period was chosen to ensure changes in metabolic parameters. To estimate 
daily energy requirements, three 24-hour recall interviews (2 on weekdays, 1 on weekend) and a 
30-day dietary inventory were administered to the subjects. A food recall kit containing standard 
portion sizes was used in a face-to-face interview, assessing the food intake of the previous 24-
hours. An average of the questionnaires was utilized to determine daily caloric requirements. The 
positive energy challenge was consistent with the typical North American diet: 50% 
carbohydrates, 35% fat, and 15% protein. Throughout 7-days at time 0900, 1200, and 1700, 
subjects consumed meals with caloric and nutritional content calculated using Food Processor 
SQL (version 9.5.0.0; ESHA Research, Salem, OR). A laboratory member was present through 
the duration of all meals. Average caloric content was 2969 kcal pre-overfeeding and 5471 kcal 
during overfeeding [29]. While participating in the study, subjects were requested to refrain from 
consuming additional calorie-containing beverages, drinking alcohol, or taking 
drugs/medications.  
 
Measured Variables 
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Various physical, anthropometric and biochemical markers were assessed after a 12-hr fasting 
period, before and after the 7-day overfeeding period. These are outlined below: 
 
Anthropometric measurements  
During all anthropometric measurements subjects wore a light standardized hospital gown. Total 
body weight was assessed on a platform scale balance (Health O Meter, IL) and height was 
measured using a fixed stadiometer, to the nearest 0.1 kilogram and centimeter, respectively. 
Body mass index (BMI) was calculated by dividing the participant’s weight in kilograms by 
height in meters squared (kg/m2). Both waist and hip circumference were evaluated using a 
measuring tape to the nearest 0.1 centimeter. 
 
Body composition measurements 
Body composition was assessed using dual-energy X-ray absorptiometry (DXA Lunar Prodigy; 
GE Medical Systems, Madison, WI). The scan can differentiate between fat, lean, and bone 
mass, and can therefore determine percent body fat (%BF), trunk fat (%TF), android fat (%AF), 
and gynoid fat (%GF)  [37] (Method previously described by us [38]). Study subjects were 
classified as underweight, normal weight, overweight, and obese based on percentage body fat 
recommendations by Bray (for males aged 20-39: underweight= <8.0%, normal weight= 8-
20.9%, overweight= 21-25.9%, or obese= >26.0%) [39]. 
 
Serum measurements 
Venous blood was collected from subjects and after processing, serum was stored at -80°C. 
Serum total cholesterol, high-density lipoprotein cholesterol (HDL-c), triacylglycerols (TGs), 
47 
 
47 
 
and glucose concentrations were determined by Synchron reagents using an Lx20 clinical 
chemistry analyzer (Beckman Coulter Inc., CA, USA). The concentration of serum insulin was 
measured utilizing the Immulite 2500 immunoassay analyzer (Siemens, Los Angeles, CA). The 
homeostasis model assessment (HOMA) was used to estimate indices of pancreatic β-cell 
function (HOMA-β: [20 x insulin (mU/L)/(glucose (mmol/L) - 3.5)]) and insulin resistance 
(HOMA-IR: [insulin (mU/L) x glucose (mmol/L)/22.5)]). The Friedwald equation (total 
cholesterol – HDL-c – TG/2.2) was used to calculate low-density lipoprotein cholesterol (LDL-
c). Serum total GLP-1 was measured in duplicate using enzyme-linked immunosorbent assay 
(ELISA) kits (EMD Millipore, St. Charles, MO). The intra-assay variation ranged from 3.4% to 
4.2%, and the inter-assay variation (n = 4) was 5.7%. 
 
Statistical Analysis 
All data are presented as mean ± S.E. unless stated otherwise. Data not normally distributed were 
log-transformed (concentrations of fasting: serum GLP-1, triacylglycerols, insulin, HOMA-IR 
and HOMA-β) where appropriate. As well, all data was analyzed using SPSS (Version 19) and 
statistical tests were two-sided with significance set at a P-value of 0.05. Because of the small 
sample size (n=3) underweight subjects were combined with normal weight subjects (total 
n=30). Additionally, as there were a small number of overweight individuals (n=14), these 
subjects were combined with obese subjects (total n=42). 
The differences between various markers of adiposity, insulin resistance, and lipid metabolism, 
and fasting GLP-1 concentration before and after the overfeeding protocol, were assessed 
utilizing paired t-test analysis. Additionally a two-factor ANOVA (repeated measures) was used 
to examine the overfeeding-adiposity interaction of measured variables. One-way ANOVA (with 
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Bonferroni post hoc tests) was utilized to assess the differences of variables between adiposity 
groups at baseline. 
Spearman correlation analysis was completed to assess the relationship between a) baseline 
GLP-1 serum concentration and aforementioned variables at baseline, b) baseline GLP-1 serum 
concentration and change in the variables; c) change in serum GLP-1 and change in the 
variables; and d) baseline variables and  change in serum GLP-1. Additionally partial correlative 
analysis was completed controlling for potential confounding factors.  
 
RESULTS 
Pre- and Post- Overfeeding Descriptive Statistics 
Biochemical and physical measurements prior-to and after the overfeeding challenge are 
presented in Table 1. Changes in anthropometrics, body composition and measures of glucose 
and lipid metabolism were previously described by us [31, 32, 40]; nevertheless, it was evident 
that the one-week overfeeding challenge increased body weight, adiposity, serum lipids, insulin 
and insulin resistance. After a one week energy surplus, circulating GLP-1 concentration rose in 
the cohort. The pre- and post- overfeeding fasting concentrations of GLP-1 were increased from 
36.84±3.16 pmol/L at baseline to 42.39±3.18 pmol/L, after overfeeding. The average percent 
change in GLP-1 through the overfeeding study was 24.10±5.85 %. However based on 2-way 
ANOVA repeated measure analysis, there was no significant difference between normal weight 
and overweight/obese subjects for the increase in serum GLP-1 (P=0.590). Furthermore, there 
was no significant difference between the normal weight and overweight/obese group for fasting 
GLP-1 concentration at baseline (t-test: P=0.876). 
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Baseline correlations of GLP-1 with body composition and markers of lipid/glucose 
metabolism 
Table 2 characterizes the baseline relationships between GLP-1 and the markers of 
adiposity, and lipid/glucose metabolism, utilizing Spearman correlation analysis. In the entire 
cohort, fasting GLP-1 concentration was negatively associated with HDL-c concentration and 
positively associated with triacylglycerol concentration. Also a positive relationship was evident 
between GLP-1 and the ratio of total cholesterol to HDL-c. When the cohort was grouped based 
on adiposity status (based on Bray recommendations), no relationships were found between 
GLP-1 concentration and the measured variables in the normal weight group. However, in the 
overweight/obese group, GLP-1 concentration remained significantly correlated with HDL-c, 
triacylglycerol concentration, and the ratio of total cholesterol to HDL-c. Interestingly, in the 
overweight/obese, a positive relationship was found between GLP-1 concentration and insulin, 
HOMA-IR, HOMA-β, and percent gynoid fat. 
Due to the possible confounding effect of gynoid fat on HDL-cholesterol, 
triacylglycerols, and markers of insulin metabolism, partial correlations were performed 
controlling for gynoid fat and all analyses were repeated (data not shown).  All of the 
aforementioned relationships remained significant except for the relationship between GLP-1 
and HOMA-β in the overweight/obese group (r = 0.300, P = 0.053). 
 
Correlations between baseline GLP-1 with percent change in body composition and 
markers of lipid/glucose metabolism 
The correlative data between fasting baseline GLP-1 concentration and percent changes in the 
markers of adiposity, and lipid and glucose metabolism were also observed. In the entire cohort, 
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no relationships were present between circulating GLP-1 and changes in any of the 
measurements. However when subjects were grouped according to adiposity, a negative 
correlation was revealed between GLP-1 concentration and change in percent gynoid fat (r = -
0.349, P=0.025) in the overweight/obese group.  
 
Correlations between percent change in GLP-1 with percent change in body composition 
and markers of lipid/glucose metabolism 
Presented in Table 3 is the correlative data between percent change in GLP-1 concentration and 
percent change in markers of adiposity, and markers of lipid/glucose metabolism. In the entire 
cohort, change in GLP-1 was significantly positively associated with percent change in HDL-c, 
and triacylglycerols. When split based on adiposity status, percent change in GLP-1 was 
positively correlated with percent change in triacylglycerols and negatively correlated with 
percent change in gynoid fat in the normal weight group. However, in the overweight/obese 
percent change in serum GLP-1 was significantly positively associated with percent change in 
total cholesterol and triacylglycerols. 
 
Correlations between percent change in GLP-1 with baseline body composition and 
lipid/glucose metabolism variables 
Additionally we wanted to assess the relationship between baseline variables and percent change 
in GLP-1 (Table 4). In the entire cohort, baseline weight and BMI were positively correlated 
with percent change in GLP-1 while baseline GLP-1 was negatively correlated with percent 
change in GLP-1. The same relationships were found significant in the normal weight group, 
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when the cohort was grouped based on adiposity. However, only the negative relationship with 
baseline GLP-1 remained significant in the overweight/obese group.  
 
DISCUSSION 
In the current investigation we examined the response of circulating GLP-1 to a 7-day 
energy surplus in 72 young men of Newfoundland descent. The most notable finding was that 
GLP-1 concentration significantly increased in response to the overfeeding challenge. The rise in 
GLP-1 concentration was independent of adiposity status as the increase of GLP-1 was present in 
normal weight and overweight/obese groups. GLP-1 has been shown to have beneficial effects as 
it facilitates the glucose-dependent insulin response, lowers glucagon secretion, and induces 
satiation [7-14]. Thus current literature suggests GLP-1 secretion would increase in response to a 
positive energy challenge, counteracting the response and potentially acting as a protective 
mechanism (cessation of appetite/regulation of insulin secretion). Though this may be the case, 
studies regarding circulating GLP-1 and overfeeding in humans are few in number, and vary 
largely in terms of overfeeding time, degree of overfeeding and macronutrient composition. A 3-
day overfeeding study in which 21 subjects (15 males, 6 females) consumed 50% more calories 
than baseline requirements (energy breakdown: 20% protein, 30% fat, 50% carbohydrate) 
showed GLP-1 was unchanged over the duration of the study [35]. Similarly, Brons et al. 
overfed 26 healthy Danish young men 50% more calories than required (60% fat, 32.5% 
carbohydrates and 7.5% protein) utilizing a 5-day high fat diet and found no significant change 
in fasting circulating GLP-1 [33]. A small study on nine lean Caucasian males also found no 
significant difference in GLP-1 concentration after an overfeeding period which ceased when 5% 
of body weight was gained (average of 35 days, range of 28-43; composition: ~ 50% 
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carbohydrates, 35% fat, 15% protein) [34]. The excess calories were provided by a liquid drink 
which was used to bring total caloric intake to a value of 1.4 times the eucaloric diet. Evidently 
these studies differ in regards to subject homogeneity, length and amount of energy surplus. The 
negative results from all three studies could be due to the small sample size and/or shorter period 
of overfeeding (first two studies). The present investigation, utilizing a fairly homogenous 
sample population of young healthy men from the Newfoundland population, observed a 
significant increase in serum GLP-1 after a 7-day overfeeding challenge consistent with a typical 
North American diet (50% carbohydrates, 35% fat, and 15% protein). We suggest that the 
increase in GLP-1 was a homeostatic protective mechanism to offset the metabolic disturbance 
caused by the energy surplus.  
Previous studies have suggested that obese individuals have a lower GLP-1 secretion as 
compared to lean individuals [20, 24, 25, 41]. In our cohort, we found no significant difference 
in fasting GLP-1 concentration between overweight/obese and normal weight subjects. In the 
entire cohort we found no significant relationship between baseline GLP-1 concentration and 
markers of adiposity including BMI and percent body fat. However, in the overweight/obese 
group we found baseline GLP-1 correlated with percent gynoid fat. In general, women are more 
likely to have greater gynoid fat distribution, and having this distribution is thought to oppose 
cardiovascular diseases through more efficient fat storage/lipoprotein lipase functionality [42, 
43]. Additionally in the overweight/obese group baseline GLP-1 concentrations correlated with a 
negative change in percent gynoid fat. In other words, individuals with higher GLP-1 
concentration had a smaller change in percent gynoid fat after the positive energy challenge; 
therefore the finding suggests higher baseline GLP-1 predicted a reduced gain in percent gynoid 
fat. Moreover, change in GLP-1 was negatively associated with a change in gynoid fat within the 
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normal weight group, again proposing a protective effect of GLP-1. Nevertheless, with lack of 
large-scale studies assessing GLP-1 and overfeeding we cannot fully elucidate the predictor 
ability of baseline/change in GLP-1 on change in metabolic variables. 
 In this study we also observed the relationships between GLP-1 and markers of lipid 
metabolism and insulin resistance. At baseline when controlling for percent gynoid fat, GLP-1 
was positively correlated with triacylglycerols and markers of insulin resistance and negatively 
correlated with HDL cholesterol, in the overweight/obese group. Thus taken together, 
overweight/obese subjects with higher circulating baseline GLP-1 have a less favourable lipid 
profile (higher triacylglycerols, lower HDL cholesterol) and higher insulin resistance (increased 
HOMA-IR, HOMA-β, and insulin). This being said, studies have shown administration of GLP-
1 receptor agonists to be associated with a beneficial change in lipid profile and insulin 
resistance [44-47]. Still however, a study by de Luis et al. [48] found that after biliopancreatic 
diversion surgery in morbidly obese patients, basal GLP-1 was negatively associated with HDL-
c, consistent with our findings. Additionally it has been found that higher circulating GLP-1 in 
subjects with metabolic syndrome, are at greater risk for cardiovascular disease [49]. When we 
observed the relationship between percent change in GLP-1 and percent change in 
triacylglycerols, a positive association was found in both the normal weight and 
overweight/obese cohorts (also change in cholesterol was positively correlated with change in 
GLP-1 in the overweight/obese cohort). We theorize that the increased GLP-1 is trying to 
compensate for the increase in both triacylglycerols and total cholesterol. However, because our 
study is a forced overfeeding intervention (subjects ate 70% more calories than required a day) 
the metabolic disturbance caused by overfeeding potentially overwhelmed GLP-1’s potential 
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effect. Nevertheless more studies are necessary to elucidate the role of GLP-1 in lipid/glucose 
metabolism.  
A limitation of this investigation is that only young men (age 19-29) of Newfoundland 
descent were studied for one week; therefore similar studies are needed in females, and subjects 
of different age ranges and ethnic groups. Further large-scale overfeeding studies assessing such 
cohorts are warranted to fully elucidate the role of GLP-1 during a positive energy surplus. 
Additionally, only total human GLP-1 was measured rather than the suggested active form, GLP-
1 (7-36 amide). Active GLP-1 has a very short half-life and is found in low concentrations, 
before it is degraded by DPP-IV, while total GLP-1 gives an indication of the secretion from 
intestinal L-cells. However, total GLP-1 has been shown to positively correlate with active GLP-
1 (7-36amide) concentration [50]. Furthermore, although macronutrient composition was 
relatively constant, we did not account for the composition of fat (polyunsaturated, saturated, etc) 
or carbohydrate (complex vs. simple sugars). 
 
CONCLUSION 
Overall, our study investigated the response of fasting GLP-1 concentration to a 7-day 
overfeeding protocol in a total of 72 young men from the Canadian province of Newfoundland. 
In response to the short term energy surplus, circulating GLP-1 significantly increased in the 
entire cohort, regardless of adiposity. We suggest that the increased GLP-1 may act as a 
protective mechanism to counteract the positive energy challenge. Additionally at baseline, there 
was no significant difference in fasting GLP-1 concentration between the lean and 
overweight/obese groups. However at baseline, GLP-1 was positively correlated with 
triacylglycerols and markers of insulin resistance, and negatively associated with HDL-c in 
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overweight/obese individuals. Also in this group, baseline GLP-1 was negatively associated with 
percent change in percent gynoid fat. Percent change in GLP-1 was associated with percent 
change in specific variables of lipid metabolism (triacylglycerols, total cholesterol) in the 
overweight/obese group. Although the positive relationship between percent change in 
triacylglycerols and percent change in GLP-1 was present in the normal weight group, a negative 
relationship existed between percent change in gynoid fat and percent change in GLP-1. Our 
results suggest that GLP-1 can potentially serve as a protective factor in obesity and it is 
involved in lipid/glucose metabolism and fat distribution. 
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CHAPTER 4: SUMMARY 
The current global obesity epidemic puts more of the population at a greater risk 
of diabetes, cardiovascular complications, and certain forms of cancer. Although 
increased caloric intake and decreased energy expenditure are fundamental roots of 
increased adiposity, obesity is a multi-faceted condition and is therefore influenced by 
environmental and genetic factors. Moreover, various circulating peripheral hormones act 
as signals to the central nervous system (and other peripheral tissues) influencing energy 
homeostasis, metabolism, appetite and therefore, body composition. Hormones secreted 
from the GI tract, the largest endocrine organ in the body, are no exception as they are 
involved in energy homeostasis, influencing appetite, metabolism, and GI motility [1, 2]. 
For example ghrelin, secreted mainly from the fundus of the stomach before meals, has 
been shown to increase appetite in animal and humans [3-5]. Additionally, the gut 
hormone glucagon-like peptide-1 (GLP-1) has been described as an incretin hormone: 
helping to facilitate the glucose-dependent insulin response [6-8]. The hormone also 
decreases glucagon secretion, slows gastric secretions/motility and is suggested to 
increase satiety [9, 10]. Though studies have assessed the hormones ghrelin and GLP-1 in 
respect to human obesity, few studies exist assessing the change of gut hormones through 
a positive energy challenge. The positive energy balance, or energy surplus (calories 
consumed > calories expended) is the primary cause of weight gain and obesity, thus 
understanding metabolic and biochemical changes during such periods of overfeeding is 
of immense importance. Therefore our research goal was to investigate the response of 
two functionally related gut hormones, ghrelin and GLP-1 to a short-term overfeeding 
period involving young men. The specific research objectives were as follows: 1) to 
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observe the change of GLP-1 and ghrelin to a 7-day overfeeding intervention (70% more 
calories than required at baseline); 2) to assess the difference in circulating GLP-1 and 
ghrelin at pre and post-overfeeding between adiposity (normal weight, overweight, obese) 
groups; and 3) to examine the relationships of GLP-1 and ghrelin with body composition, 
physical and biochemical markers. 
 
Seventy-two healthy young men aged 19-29 from Newfoundland were overfed 
70% more calories than each required for one week. The diet consisted of 50% 
carbohydrates, 35% fat, and 15% protein which is typical of North America dietary 
consumption patterns. Aforementioned physical and biochemical measurements were 
taken at fasting before (morning Day 1) and after (morning Day 8) the overfeeding 
protocol. Serum ghrelin was measured using an EIA method, and GLP-1 was measured 
using an ELISA method, before and after the positive energy challenge. 
 
As expected, circulating GLP-1 increased due to the overfeeding challenge. 
However to our surprise, circulating ghrelin also increased. After subjects were split into 
adiposity groups of normal weight, overweight and obese, there were no differences 
found for baseline ghrelin and GLP-1 between these groups. Additionally, there was no 
difference for the change in ghrelin and GLP-1 due to overfeeding between normal 
weight, overweight and obese cohorts. At baseline, circulating ghrelin was negatively 
associated with weight and BMI in the normal weight group, and negatively associated 
with BMI in the overweight group. Also at baseline, circulating GLP-1 was inversely 
correlated with HDL-cholesterol and positively correlated with triacylglycerols and 
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markers of insulin resistance in the overweight/obese group. Moreover, baseline ghrelin 
was negatively correlated with change in weight and BMI in the overweight group, and 
positively correlated with change in BMI in the obese group. Interestingly, baseline GLP-
1 was negatively associated with change in percent gynoid fat in overweight/obese 
subjects. However, change in circulating GLP-1 was positively associated with percent 
change in triacylglycerol in normal weight and overweight/obese groups. When observing 
the normal weight group, percent change of GLP-1 was inversely correlated with percent 
change in gynoid fat. Furthermore in the overweight/obese subjects, percent change in 
GLP-1 was positively associated with percent change in total cholesterol. 
 
The present study only investigated a homogenous population of young 
Newfoundland men aged 19-29. Future overfeeding studies observing larger-scale 
populations are needed to fully elucidate the role of ghrelin and GLP-1 during a positive 
energy challenge. Specifically populations including females and subjects of varying 
ethnic groups and age ranges are needed for further investigations. Also as mentioned, 
there are over 20 gut hormones secreted from the gastrointestinal tract [11]. However due 
to various limitations, only the functionally related hormones of ghrelin and GLP-1 were 
assessed in this study. 
 
Overall, our results showed that circulating GLP-1 and ghrelin increased in a 
cohort of young Newfoundland men due to a 7-day positive energy challenge regardless 
of adiposity status. We propose the increase in GLP-1 is likely a protective role, 
counteracting the energy surplus. We also theorize that the rise in ghrelin could 
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potentially be attempting to offset the rising insulin resistance present during the 
overfeeding protocol. Hence the gut hormones ghrelin, and GLP-1 are involved in the 
regulation of body composition and lipid/glucose metabolism. 
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